Karyopharm Therapeutics (NASDAQ:KPTI) Posts Earnings Results, Beats Estimates By $0.21 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) announced its earnings results on Thursday. The company reported ($1.24) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.21, FiscalAI reports. The company had revenue of $35.07 million during the quarter, compared to the consensus estimate of $31.40 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Karyopharm said its phase III SENTRY trial in myelofibrosis met the main spleen response endpoint, with SVR35 at week 24 of 50% versus 28% for ruxolitinib alone and no new safety signals.
• The company highlighted an encouraging overall survival signal in SENTRY, along with early variant allele frequency reductions that it believes may suggest disease-modifying activity.
• XPORT-EC-042 in endometrial cancer has completed enrollment, and Karyopharm still expects top-line data in mid-2026 for the biomarker-driven maintenance study.
• Management argued that its endometrial cancer program targets a large subgroup of TP53 wild-type, MMR-proficient patients and emphasized that the 60 mg weekly selinexor dose with mandated antiemetics should improve tolerability versus earlier studies.
• First-quarter revenue rose to $35.1 million from $30.0 million a year ago, but management said underlying XPOVIO demand fell versus last year due to new competition; it reaffirmed full-year 2026 revenue and expense guidance and said liquidity should last into late Q3 2026.

Karyopharm Therapeutics Trading Up 1.3%

Shares of Karyopharm Therapeutics stock traded up $0.11 during trading on Thursday, hitting $8.96. The stock had a trading volume of 774,013 shares, compared to its average volume of 815,946. Karyopharm Therapeutics has a 12 month low of $3.65 and a 12 month high of $10.99. The firm has a market cap of $202.08 million, a price-to-earnings ratio of -0.54 and a beta of 0.80. The business’s 50-day moving average is $7.91 and its 200 day moving average is $7.24.

Hedge Funds Weigh In On Karyopharm Therapeutics

Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC bought a new position in shares of Karyopharm Therapeutics during the 4th quarter valued at about $74,000. Baird Financial Group Inc. purchased a new stake in Karyopharm Therapeutics in the second quarter worth approximately $45,000. Tudor Investment Corp ET AL bought a new position in Karyopharm Therapeutics during the fourth quarter valued at approximately $95,000. XTX Topco Ltd purchased a new position in shares of Karyopharm Therapeutics during the second quarter worth approximately $56,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $135,000. Institutional investors own 66.44% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on KPTI. Robert W. Baird reduced their price objective on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a research note on Wednesday, March 25th. Piper Sandler reiterated an “overweight” rating and issued a $16.00 target price (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th. Rodman & Renshaw upgraded shares of Karyopharm Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. Cantor Fitzgerald assumed coverage on shares of Karyopharm Therapeutics in a report on Thursday, February 5th. They set an “overweight” rating on the stock. Finally, HC Wainwright raised their price objective on shares of Karyopharm Therapeutics from $8.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $17.17.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.